Bayer NDA Filing For Renal Cancer Agent May Be Based On Phase II Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer may submit an NDA for its Raf kinase inhibitor BAY 43-9006 using Phase II data in renal carcinoma, Bayer Health Care Chairman Arthur Higgins said.
You may also be interested in...
Bayer/Onyx Kidney Cancer Drug NDA Will Wait For Phase III Results
Onyx says the results of the Phase II study for BAY 43-9006 are favorable and support its decision to proceed with its Phase III trial. Its partner, Bayer, previously said the filing could be based on Phase II results.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.